Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: Results of a pilot study

Mayo Clinic Proceedings

Volumn 71, Issue 5, 1996, Pages 431-436

  Sandborn, William J ^a   Landers, Carol J ^a   Tremaine, William J ^b   Targan, Stephan R ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ENEMA; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NICOTINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0029913679     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.5.431     Document Type: Article

References (51)

1. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86:202210
2. Duerr RH. Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100:1590-1596
3. Colombel JF, Reumaux D, Duthilleul P, Noel LH, Gower-Rousseau C, Paris JC, et al. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol Clin Biol 1992; 16:656660
4. Oudkerk Pool M, Ellerbroek PM, Ridwan BLJ, Goldschmeding R, von Blomberg BM, Pena AS, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis: a correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993; 34:46-50
5. Peen E, Aimer S, Bodemar G, Ryden BO, Sjolin C, Tejle K, et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993:34:56-62
6. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992; 33:668-674
7. Nielsen H, Wiik A, Elmgreen J. Granulocyte specific antinuclear antibodies in ulcerative colitis: aid in differential diagnosis of inflammatory bowel disease. Acta Pathol Microbioi Immunol Scand [C] 1983:91:23-26
8. Snook JA, Chapman RW, Fleming K, Jewell DP. Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1989; 76:30-33
9. Seibold F. Weber P, Klein R, Berg PA, Wiedmann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33:657-662
10. Rump JA, Scholmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181:406-413
11. Hardarson S, Labrecque DR, Mitros FA, Neu G A, Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases: high prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am J Clin Pathol 1993:99:277-281
12. Patel RT, Pall AA, Stokes R, Birch D, Hail C, Adu D, et al. Autoantibody prevalence and association in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1994; 6:705-709
13. Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C. et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103:456-461
14. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107:532-536
15. Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995; 108:428-433
16. Yang H, Rotter JI. Toyoda H, Landers C, Tyran D. McElree CK. et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytophismic antibodies) markers. J Clin Invest 1993; 92:1080-1084
17. Yang H, Targan SR, Toyoda H, Tyan D, Landers C, McElree CK, et al. Exploring the mode of inheritance of ANCA+ and ANCAulcerative colitis at the HLA locus [abstract]. Gastroenterology 1993; 104(Suppl):A804
18. Annese V, Piepoli A, Napolitano G, Perri F, Caruso N, Ciavarella G, et al. Are HLA and pANCA markers of genetic heterogeneity in ulcerative colitis? [abstract]. Gastroenterology 1995; lOS(Suppl): A771
19. DuerrRH, Chensny LJ, WongCT, Neigut DA. Homozygosity for an HLA class II group haplotype is associated with p-ANCA positive and familial ulcerative colitis [abstract]. Gastroenterology 1995; 108(Suppl):A812
20. Reumaux D, Delecourt L, Colombel JF, Noel LH, Duthilleul P, Cortot A. Anti-neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis [letter]. Gastroenterology 1992; 103:1706
21. Monteleone G, Doldo P, Marasco R, Parrello T, Imeneo M, De Medici A, et al. Perinuclear neutrophil autoantibodies (p-ANCA) in unaffected relatives of patients with ulcerative colitis (UC): suggestions against familial aggregation [abstract]. Gut 1994; 35(Suppl 4):A31
22. Mehal WZ, Lo SK, Wordsworth PB, Chapman RW, Fleming KA. HLA DRw52a and Dw2 are not associated with the development of and neutrophil antibody typel (ANCA1) in ulcerative colitis (UC) [abstract]. Gastroenterology 1993; 104(Suppl):A743
23. Gracia Casanova M, Oudkerk Pool M, Pena AS, Crusius JBA, Fonk JCM, Schieveld S, et al. A subgroup of ulcerative colitis (UC) defined with genetic (HLA-DR) and immunological (pANCA) markers [abstract]. Gastroenterology 1993; 104(Suppl):A709
24. Farrant JM, Bunce M, Artlett C, Landers C, Welsh KI, Toyoda H, et al. HLA DR2 is a susceptibility marker for UC in British patients irrespective of ANCA positivity [abstract]. Gastroenterology 1994; 106(Suppl):A679
25. Takaishi H, Watanabe M, Inoue N, Ueno Y, Sugimura K, Asakura H, et al. Autoantibodies in Japanese patients with ulcerative colitis are not related to a genetic marker (HLA class II) [abstract]. Gastroenterology 1994; 106(Suppl):A780
26. Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995; 108:423-427
27. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90:740-747
28. Reumaux D, Colombel JF, Heresbach D, Duclos B, Chaussade S, Belaiche J, et al. Antineutrophil cytoplasmic auto-antibodies in sera from patients after proctocolectomy for ulcerative colitis [abstract]. Gastroenterology 1993; 104(Suppl):A769
29. Vecchi M, Gionchetti P, Bianchi MB, Belluzzi A, Meucci G, Campieri M, et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis [letter]. Lancet 1994;344:886-887
30. Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MR. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994; 81:724-726
31. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991; 100:350-358
32. Jarnerot G, Lennard-Jones J, Bianchi-Porro G, Brynskov J, Campieri M, Present D. Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 1991; 4:93-98
33. Biddle WL, Miner PB Jr. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990; 99:113-118
34. Farmer RG. Long-term prognosis for patients with ulcerative proctosigmoiditis (ulcerative colitis confined to the rectum and sigmoid colon). J Clin Gastroenterol 1979:1:47-50
35. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990;31:329-333
36. Sutherland LR, Martin F, Gréer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92:1894-1898
37. Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner PB Jr. 5Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94:10751079
38. Böyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest Suppl 1968; 97:1-106
39. Chng HH, Ganz T, Saxon A. The utility of detecting of autoantibodies against neutrophil cytoplasmic components in Wegener's granulomatosis. Ann Allergy 1989; 63:411-416
40. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1-15
41. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988:318:1651-1657
42. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37:219-228
43. Specks U, Homburger HA. Anti-neutrophil cytoplasmic antibodies. Mayo Clin Proc 1994; 69:1197-1198
44. Devulder F, Reumaux D, Colombel JF, Cortot A, Duthilleul P. Determination of antineutrophil cytoplasmic auto-antibodies (ANCA) specificity in sera from patients with inflammatory bowel disease. Gastroenterology 1994; 106(Suppl):A672
45. Ellerbroek PM, Oudkerk Pool M, Ridwan BU, Dolman KM, von Blomberg BM, von dem Borne AE, et al. Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J Clin Pathol 1994; 47:257-262
46. Billing P, Tahir S, Calfin B, Gagne G, Cobb L, Targan S, et al. Nuclear localization of the antigen detected by ulcerative colitisassociated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995; 147:979-987
47. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15:293-299
48. Targan SR, Landers C, Vidrich A, Czaja AJ. High-liter antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108:1159-1166
49. Vecchi M, Bianchi M, Torgano G, Meucci G, Omodei P, Levati M, et al. Anti-neutrophil cytoplasmic antibodies (p-ANCA) are more prevalent in ulcerative colitis patients with clinically aggressive disease [abstract]. Gastroenterology 1992; 102(Suppl):A708
50. Boerr LA, Sambuelli AM, Katz S, Sole L, Gil A, Gonçalves S, et al. Clinical heterogeneity of ulcerative colitis in relation to frequency of pANCA reactivity [abstract]. Gastroenterology 1994; 108(Suppl): A785
51. Targan S, Landers C, Vidrich A, MacDermott RP. Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) are spontaneously produced by B-cells from involved and uninvolved mucosa of ulcerative colitis (UC) patients [abstract]. Gastroenterology 1994; 106(Suppl):A781